Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity
Seeking Alpha,
Summary Xenon Pharmaceuticals appears undervalued heading into a pivotal phase two MDD trial readout due by the end of November.